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Summary
 
A cDNA encoding a novel human chemokine was isolated by random sequencing of cDNA
clones from human monocyte-derived macrophages. This protein has been termed macrophage-
derived chemokine (MDC) because it appears to be synthesized specifically by cells of the mac-
rophage lineage. MDC has the four-cysteine motif and other highly conserved residues charac-
teristic of CC chemokines, but it shares 
 
,
 
35% identity with any of the known chemokines.
Recombinant MDC was expressed in Chinese hamster ovary cells and purified by heparin–
Sepharose chromatography. NH
 
2
 
-terminal sequencing and mass spectrophotometry were used
to verify the NH
 
2
 
 terminus and molecular mass of recombinant MDC (8,081 dalton). In mi-
crochamber migration assays, monocyte-derived dendritic cells and IL-2–activated natural
killer cells migrated to MDC in a dose-dependent manner, with a maximal chemotactic re-
sponse at 1 ng/ml. Freshly isolated monocytes also migrated toward MDC, but with a peak re-
sponse at 100 ng/ml MDC. Northern analyses indicated MDC is highly expressed in macro-
phages and in monocyte-derived dendritic cells, but not in monocytes, natural killer cells, or
several cell lines of epithelial, endothelial, or fibroblast origin. High expression was also de-
tected in normal thymus and less expression in lung and spleen. Unlike most other CC
chemokines, MDC is encoded on human chromosome 16. MDC is thus a unique member of
the CC chemokine family that may play a fundamental role in the function of dendritic cells,
natural killer cells, and monocytes.
 
C
 
hemokines comprise a family of secreted proteins that
attract and activate a variety of cell types, generally
augmenting the immune response (reviewed in references
1–3). Chemokines have been classified into two subfamilies
based on the relative positions of the first two of four con-
served cysteine residues. In the CC subfamily, the first two
cysteines are adjacent, whereas in the CXC subfamily, they
are separated by one amino acid. The CC chemokines usu-
ally act on monocytes, T lymphocytes, and in some cases,
eosinophils, basophils, or mast cells. In contrast, the CXC
chemokines generally act upon neutrophils. Further, the
chemokines macrophage inflammatory protein (MIP)
 
1
 
-1
 
a
 
 (4),
stromal-derived factor (5, 6), and Exodus (7) have been im-
plicated in the regulation of hematopoiesis.
The repertoire of known human CC chemokines is
expanding rapidly and now includes MIP-1
 
a
 
, MIP-1
 
b
 
,
RANTES, I-309, monocyte chemotactic proteins 1, 2, and 3
(MCP-1, -2, -3; 8–13), and the recently described chemo-
kines MCP-4 (14–16), eotaxin (17, 18), HCC-1 (19), thymus
and activation regulated chemokine (TARC) (20), and Exo-
dus (7). These proteins are 70–100 amino acids in length and
have  25–70% identity with each other. Chemokines act
through G protein–coupled receptors, which have a charac-
teristic seven-transmembrane structure. Five CC chemokine
receptors have been described: CCR-1 (21, 22) binds MIP-
1
 
a
 
, RANTES, and MCP-3 (23, 24); CCR-2 binds MCP-1
(25), MCP-3 (26), and MCP-4 (14-16); CCR-3 (18, 27)
binds eotaxin, MCP-3, RANTES, and MCP-4 (15); CCR-4
(28) binds MIP-1
 
a
 
, RANTES, and MCP-1; and CCR-5 (29,
30) binds MIP-1
 
a
 
, MIP-1
 
b
 
, and RANTES. In addition, mac-
rophage-tropic strains of HIV appear to require one of these
receptors, primarily CCR-5, as a cofactor for infection (31–35).
The present study describes the cloning and characteriza-
tion of a novel human CC chemokine, macrophage-derived
 
1
 
Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; GAPDH,
glyceraldehyde phosphate dehydrogenase; I-HUVEC, immortalized hu-
man umbilical vein endothelial cells; LDL, low density lipoprotein; MCP,
monocyte chemotactic proteins; MDC, macrophage-derived chemokine;
MIP, macrophage inflammatory protein; TARC, thymus and activation
regulated chemokine.
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chemokine (MDC). MDC is not closely related to the
other chemokines and has not been previously identified in
the publicly available databases. MDC is produced by mac-
rophages and dendritic cells, and it is chemotactic for mono-
cytes, monocyte-derived dendritic cells, and IL-2–activated
natural killer cells.
 
Materials and Methods
 
Isolation of a cDNA-encoding MDC.
 
RNA Stat-60 (Tel-Test,
Inc., Friendswood, TX) was used to isolate poly (A
 
1
 
) RNA from
monocyte-derived macrophages from a normal human donor.
cDNA generated from this RNA (Invitrogen Copy Kit; Invitro-
gen, San Diego, CA) was inserted into the mammalian expression
vector pRc/CMV (Invitrogen) and used to transform 
 
Escherichia
coli
 
 XL1-blue bacteria (Stratagene Corp., La Jolla, CA) (36). Plas-
mid DNA was isolated from randomly chosen individual transfor-
mants (Wizard miniprep purification system; Promega Corp., Madi-
son, WI). Approximately 300–500 bp of each end of the plasmid
inserts were sequenced on an automated sequencer (model 373;
Applied Biosystems, Foster City, CA) and compared to the Gen-
Bank “nr” database using the BLAST (37) program (National Center
for Biotechnology Information, Bethesda, MD, E-mail: Blast@ncbi.
nlm.nih.gov). Among several hundred clones sequenced, one clone,
designated pMP390, was identified as a unique sequence that con-
tained significant homology to CC chemokines. To facilitate
complete sequencing, the 2.9-kb insert of pMP390 was sub-
cloned into the vector pBluescript SK
 
2
 
 (Stratagene) and sub-
jected to nested deletion (Erase-a-Base System; Promega Corp.).
Additional clones of MDC were isolated by probing the mac-
rophage cDNA library with the insert of pMP390, which was pu-
rified by agarose gel electrophoresis and labeled (Random Primed
DNA Labeling Kit; Boehringer Mannheim, Indianapolis, IN). Fil-
ters were hybridized according to standard protocols and strin-
gently washed in 0.2
 
3
 
 SSC and 0.2% SDS at 55
 
8
 
C, as described
previously (38). Autoradiographs were exposed overnight at 
 
2
 
80
 
8
 
C
on Kodak XAR-5 film (Rochester, NY) with intensifying screens
(Amersham, Arlington Heights, IL).
 
Production of Recombinant MDC.
 
PCR was used to amplify a
fragment containing the entire coding region of the MDC cDNA
clone (Fig. 1, bases 1–403), using the primers 5
 
9
 
-GACCAA
GCTTGAGACATACAGGACAGAGCA and 5
 
9
 
-TGGATCTA
GAAGTTGGCACAGGCTTCTGG. Restriction sites added to
the primers are underlined. The PCR mix contained 0.2 
 
m
 
g of
pMP390 plasmid DNA, 1.5 mM MgCl
 
2
 
, 50 mM KCl, 10 mM
Tris, pH 8.4, 0.2 mM each dNTP, 10 
 
m
 
g/ml each primer, and
0.5 
 
m
 
l Taq polymerase (5 U/
 
m
 
l) (Boehringer Mannheim). The
reactions were incubated for 4 min at 94
 
8
 
C, followed by 30 cy-
cles of denaturation for 15 s at 94
 
8
 
C, annealing for 15 s at 60
 
8
 
C,
and extension for 30 s at 72
 
8
 
C. The PCR fragment was cloned
into the expression vector pDC1, a derivative of pRc/CMV in
which the neomycin phosphotransferase gene had been replaced
by the mouse dihydrofolate reductase gene from the vector
pSV2-dhfr (vector #37146; American Type Culture Collection,
Rockville, MD). The pDC1/MDC plasmid was linearized by re-
striction digestion within the vector sequence and electroporated
into the Chinese hamster ovary (CHO) cell line DG44, which
lacks the dihydrofolate reductase gene (39). Cells were electropo-
rated in a 0.4-cm cuvette using a gene pulser (Bio Rad Labs.,
Hercules, CA) at 290 volts, 960 
 
m
 
F. Transfectants were selected
by growth in 
 
a
 
-medium (Catalogue No. 12000; GIBCO BRL,
Gaithersburg, MD) plus 10% dialyzed FCS (Hyclone Labs., Lo-
gan, UT) in the absence of hypoxanthine and thymidine. Cells
from several hundred transfected colonies were pooled and replated
in 
 
a
 
-medium containing 20 nM methotrexate (Sigma Chemical
Co., St. Louis, MO). Colonies surviving this round of selection
were isolated and expanded in 
 
a
 
-medium containing 0.2–1.0% di-
alyzed FCS. MDC was isolated from the culture medium by pas-
sage over heparin–Sepharose CL-6B (Pharmacia, Uppsala, Swe-
den). The column was washed with 0.2 M NaCl in 20 mM Tris,
pH 8, and eluted with 0.6 M NaCl in 20 mM Tris, pH 8. The
eluted material was fractionated on an 18% acrylamide SDS-
PAGE gel (Novex, San Diego, CA) and electroblotted to polyvi-
nylidene fluoride membrane (Millipore Corp., Bedford, MA).
The band corresponding to MDC was sequenced on an auto-
mated sequencer (model 473A; Applied Biosystems).
The mature form of MDC protein (Fig. 1) was chemically syn-
thesized by Gryphon Sciences (San Francisco, CA) using 
 
t
 
-butyl-
oxycarbonyl chemistries on a peptide synthesizer (430A; Applied
Biosystems). Lyophilized protein was dissolved at 10 mg/ml in
4 mM HCl and immediately diluted to 0.1 mg/ml in PBS plus
0.1% BSA for storage at 
 
2
 
80
 
8
 
C.
 
Production of MDC Antibodies.
 
A PCR fragment encoding a
thrombin cleavage site and the mature form of MDC was inserted
into the vector pGEX-3X (Pharmacia). XL-1 blue bacteria (Strat-
agene) were transformed with the resulting plasmid to generate a
GST–MDC fusion protein. The protein was isolated from inclu-
sion bodies, digested with thrombin (Sigma Chemical Co.), and
fractionated by preparative SDS-PAGE (Tris glycine, 18% acryla-
mide). A gel slice containing the MDC fragment was excised and
emulsified with adjuvant for immunization of rabbits for poly-
clonal sera or mice for monoclonal sera. mAbs were obtained
from fusions of mouse spleen cells with NS-1 myeloma cells, ac-
cording to standard protocols (40).
 
Cell Culture.
 
The human cell lines A549 (lung epithelial; CCL-
185; American Type Culture Collection), T84 (colon epithelial;
CCL-248; American Type Culture Collection), and IMR-90 (lung
fibroblast; CCL-186; American Type Culture Collection) were
obtained. Cells were cultured in DME (GIBCO BRL) supple-
mented with 10% FCS (Hyclone Labs.), 25 mM Hepes, penicillin,
and streptomycin. Immortalized human umbilical vein endothe-
lial cells (I-HUVECs) were obtained (Dr. Jay Nelson, University
of Oregon, Eugene, OR) and cultured in RPMI (GIBCO BRL)
supplemented with 10% FCS (Hyclone Labs.), 400 
 
m
 
g/ml G418
(GIBCO BRL), 1 U/ml heparin (Sigma Chemical Co.), and 30
 
m
 
g/ml endothelial cell growth factor (Collaborative Biomedical
Products, Bedford, MA). A549 and IMR-90 cells were grown to
70–80% confluency and cultured in the presence or absence of 10
ng/ml TNF-
 
a
 
 (R & D Syst. Inc., Minneapolis, MN) for 6 h. T84
cells were treated for 1 d with TNF-
 
a
 
 (5 ng/ml), TGF-
 
b
 
 (1 ng/ml;
R & D Syst. Inc.), or interferon-
 
g
 
 (200 U/ml; PeproTech,
Rocky Hill, NJ). For Northern blotting, monocytes were isolated
from PBMC using histopaque gradients (Sigma Chemical Co.)
and adherence to tissue culture plastic. Cells were cultured for 6 d
to allow differentiation into macrophages (41).
PBMC for chemotaxis assays were obtained from buffy coats
of healthy donors. Blood was washed once with PBS to remove
plasma and platelets and centrifuged on Ficoll (Biochrom, Berlin,
FRG) at 600 
 
g
 
 at room temperature. PBMC were collected from
the interface, washed twice with PBS, and resuspended in RPMI
1640 medium (Biochrom) with 1% FCS (Hyclone Labs.).
Dendritic cells were obtained from PBMC as previously re-
ported (42), according to the procedure described by Sallusto et al.
(43). In brief, purified monocytes were obtained from buffy coats
by centrifugation through Ficoll and Percoll gradients. Cells were 
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further purified by negative selection with a cocktail of anti-
CD19 and anti-CD2 magnetic beads. Cells were cultured in RPMI
(Biochrom) containing 10% FCS (Hyclone Labs.), supplemented
with 50 ng/ml GM-CSF and 20 ng/ml IL-13. They were nor-
mally used between days 6 and 8 of culture. These cells were
 
.
 
80% CD1a
 
1
 
, 
 
.
 
90% MHC class II
 
1
 
, 
 
,
 
10% CD14
 
1
 
, 
 
,
 
2%
CD3
 
1
 
, and 
 
,
 
4% CD20
 
1
 
. For some experiments, cells were further
depleted of CD14
 
1
 
 cells (
 
,
 
1% CD14
 
1
 
) by anti-CD14–coated
Dynabeads (Unpath, Milan, Italy).
Natural killer cells were obtained from monocyte-depleted
PBMC by centrifugation through discontinuous Percoll gradients
(47, 49, and 52%), as previously described (44). Low density cells
were further depleted of contaminating T lymphocytes by pan-
ning with anti-CD6 mAb (50 ng/ml). Contaminating monocytes
were eliminated by incubation with anti-CD14–coated Dyna-
beads (Unpath). Purified preparations of natural killer cells (10
 
6
 
/ml)
were cultured with an irradiated lymphoblastoid cell line (10
 
5
 
/ml)
(44) in the presence of IL-2 (250 U/ml; Eurocetus, Milan, Italy).
Proliferating cells had the phenotype of natural killer cells and
were CD14
 
2
 
 and CD3
 
2
 
.
 
Migration Assay.
 
Cell migration was evaluated using a chemo-
taxis microchamber technique, as previously described (42). 27-
 
m
 
l aliquots of chemoattractant solution or control medium
(RPMI 1640 with 1% FCS) were added to the lower wells of a
chemotaxis chamber (NeuroProbe, Captain John, MD). A poly-
carbonate filter (5 
 
m
 
m pore size; NeuroProbe) was layered onto
the wells and covered with a silicon gasket and top plate. For mi-
gration of natural killer cells, the filters were coated with 200 
 
m
 
g/
ml gelatin and 10 
 
m
 
g/ml fibronectin. 50 
 
m
 
l of cell suspension
(0.7–1.5 
 
3
 
 10
 
6
 
/ml) were seeded in the upper chamber. The
chamber was incubated at 37
 
8
 
C in a humidified chamber in the
presence of 5% CO
 
2
 
 for 1.5 to 2 h. After incubation, filters were
removed and stained with Diff-Quik (Baxter s.p.a., Rome, Italy).
Five high power oil-immersion fields (100
 
3
 
) were counted. Re-
sults are expressed as the mean number of migrated cells. Each
experiment was performed in triplicate.
 
Northern Blotting.
 
The probe for Northern hybridizations was
generated by PCR amplification of bases 102–461 of the MDC
cDNA sequence using the primers 5
 
9
 
-TCTATCTAGAGGCCC-
CTACGGCGCCAACATGGAAG and 5
 
9
 
-AATGGATCCA-
CAGCACGGAGGTGACCAAG. Restriction sites added to the
primers are underlined. The fragment was gel purified and labeled
with [
 
32
 
P]CTP and [
 
32
 
P]TTP (DuPont New England Nuclear,
Boston, MA) by random priming (Boehringer Mannheim). RNA
was isolated from cell lines and cultured macrophages using RNA
Stat-60 (Tel-Test, Inc.). Total RNA (20 
 
m
 
g) was fractionated on
0.8% agarose formaldehyde gels, transferred to nitrocellulose, hy-
bridized, and washed under stringent conditions as described (38).
Autoradiographs were exposed at 
 
2
 
80
 
8
 
C with intensifying screens
for 3 h (glyceraldehyde phosphate dehydrogenase [GAPDH] and
MDC) or 8 h (MCP-1). Multiple tissue Northern blots (Clon-
tech, Palo Alto, CA) were probed and washed under stringent
conditions according to the manufacturer’s recommendations.
Films were exposed at 
 
2
 
80
 
8
 
C with intensifying screens for 16 h.
 
Chromosome Localization.
 
Hybrid mouse or hamster cell lines
containing a single human chromosome (Coriell Institute, Cam-
den, NJ) were screened by PCR for the presence of the MDC
gene. Reaction conditions were as described above, using 0.5 
 
m
 
g
of genomic DNA from each cell line as templates with the prim-
ers 5
 
9
 
-TATTGGATCCGTTCTAGCTCCCTGTTCTCC and
5
 
9
 
-CCAAGAATTCCTGCAGCCACTTTCTGGGCTC, which
amplify bases 676–1,042 of the MDC cDNA sequence (Fig. 1).
The identity of the PCR product from the positive cell line was
verified by hybridization to an internal oligonucleotide comple-
mentary to bases 246–266 of the MDC cDNA.
 
Computer Analysis.
 
Protein comparisons (Fig. 2) were per-
formed with the GeneWorks program (IntelliGenetics, Mountain
View, CA).
 
Results
 
Random clones from a human macrophage cDNA library
were partially sequenced and electronically compared to
the GenBank Non-Redundant (nr) database of sequences
(our manuscript in preparation). One clone contained a se-
quence that encoded a peptide with 
 
.
 
30% identity to por-
tions of RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
. This fragment
was used to screen the same macrophage library for addi-
tional clones. The sequence of the full-length cDNA ob-
Figure 1. Sequence and deduced translation of the MDC cDNA. The
leader sequence is in italics; the mature protein is in bold type. The ma-
ture NH2 terminus was confirmed by amino acid sequencing of recombi-
nant MDC produced in CHO cells (GPYGANMEDSV . . .). Alu repeats
(68) are present in the following positions: bases 1204–1482, 1530–1805,
and 2335–2443. The cDNA sequence of MDC has been deposited in
EMBL/GenBank/DDBJ under the accession number U83171. 
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tained is presented in Fig. 1. It contains an open reading
frame of 93 amino acids that encodes a novel CC chemokine,
designated MDC. The cDNA is considerably longer than
that of other chemokines, and it includes three Alu repeats
in the 3
 
9
 
 noncoding region.
MDC has 28–34% amino acid identity with other CC
chemokines. It contains the characteristic four-cysteine motif
in addition to nine other residues that are very highly con-
served in this family (Fig. 2). Comparison with other chemo-
kines also suggests the first 24 amino acids of MDC consti-
tute a leader sequence, which is consistent with von Heijne’s
rules governing signal cleavage (45). To confirm the pre-
dicted NH
 
2
 
 terminus of the mature peptide, the MDC cDNA
was cloned into an expression vector for stable transfection
of CHO cells. Protein was purified from culture superna-
tants by heparin–Sepharose chromatography and gel frac-
tionation (Fig. 3). NH2-terminal sequencing of the band
migrating at the expected position of MDC yielded the se-
quence GPYGANMEDSV, confirming the predicted NH2
terminus of the mature protein. Amino acid analysis and
mass spectrophotometry of the mature protein were consis-
tent with the predicted amino acid composition and mo-
lecular weight (8,081 dalton) (data not shown).
MDC Gene Expression in Human Cells. Because the MDC
clone was isolated from a human macrophage cDNA library,
its expression during differentiation of monocytes into mac-
rophages was examined. Human monocytes from a single
donor were cultured on a series of tissue culture plates, and
cells from individual plates were harvested after 0, 2, 4, or 6 d.
Under these conditions, monocytes differentiate into mac-
rophages by day 6 (36, 41). A Northern blot of RNA from
the cells harvested at each time point was probed with the
MDC cDNA. No signal was detectable in RNA from
freshly isolated monocytes, whereas a very strong signal was
generated from cells that had differentiated into macrophages
after 6 d of culture (Fig. 4 A).
MDC gene expression was examined further by treating
the human cell line HL60 with either 1% DMSO or 50
ng/ml PMA. Treatment with DMSO induces differentia-
tion of HL60 cells into a granulocytic cell type, whereas
PMA induces their differentiation toward the macrophage
lineage (46). After 3 d of PMA treatment, the macrophage-
like cells clearly expressed MDC message, although the
level of expression was less than that of monocyte-derived
macrophages (Fig. 4 B). No MDC expression was seen af-
ter 1 d of PMA treatment or in untreated cells, nor was ex-
pression detectable in the granulocytic cells generated by
treatment with DMSO for 1 or 3 d.
Northern blotting was also used to examine the expres-
sion of MDC in dendritic cells and natural killer cells de-
rived from human PBMC (see Materials and Methods).
Figure 2. Comparison of the mature form of human MDC with the
known human CC chemokines. (A) Direct comparison of amino acid se-
quences. Residues conserved in at least 10 of the 12 sequences are shaded;
the exceptions are boxed and unshaded. Dashes are inserted to optimize
alignment of the sequences. (B) Dendrogram analysis illustrating the simi-
larity of the mature forms of the CC chemokines. Percent identity with
MDC is indicated in parentheses.
Figure 3. Purification of recombinant MDC from CHO cells. A PCR
fragment containing bases 1–403 of the MDC cDNA was subcloned into
a mammalian expression vector driven by the CMV promoter and trans-
fected into CHO cells. Culture supernatant from an individual transfected
clone was harvested 4 d after cells reached confluency. MDC in the media
was concentrated and purified by binding to a heparin-Sepharose column
in 0.35 M NaCl. The left panel shows the column chromatogram. Frac-
tions collected were flowthrough (FT), 0.35 M NaCl wash (A), 0.7 M
NaCl elution (B), repeat of 0.7 M NaCl elution (C), and 1.5 M NaCl
elution (D). The right panel shows SDS-PAGE analysis (18% Tris gly-
cine) of the supernatant loaded onto the column (L) and fractions FT, B,
C, and D. MDC eluted in fraction B (arrow). The gel was transferred to
polyvinylidene difluoride membrane, and the MDC band was excised for
NH2-terminal sequencing.1599 Godiska et al.
High expression was observed in dendritic cells, which are
of the mononuclear phagocyte lineage, whereas no MDC
message was detectable in natural killer cells (Fig. 4 C). How-
ever, both of these cell types were capable of chemotaxis in
response to MDC (see below).
Other human cell types analyzed for expression of MDC
were unstimulated cultures of the lung epithelial line A549,
the lung fibroblast line IMR90, I-HUVEC, and PBMC. In
addition, to test the effect of proinflammatory cytokines on
MDC expression, the A549, IMR90, and I-HUVECs were
treated with TNF-a (10 ng/ml), and the PBMCs were
treated with PHA (1 mg/ml) plus PMA (30 ng/ml). MDC
mRNA was not detectable in the unstimulated cells by
Northern analysis, and treatment with the cytokines did not
induce MDC expression (Fig. 4 D). Induction of MCP-1
expression was readily apparent after these treatments.
To correlate the expression of MDC protein with MDC
mRNA, mAbs raised against recombinant MDC were used
for Western analysis of culture supernatants from monocyte-
derived macrophages and epithelial cell lines (Fig. 5). The re-
sults confirmed that the macrophages secreted MDC protein
into the medium, whereas the epithelial cells did not. MDC
protein expression was not affected by treatment of the mac-
rophages with low density lipoprotein (LDL) or oxidized LDL.
MDC Gene Expression in Human Tissues. The expression
pattern of MDC in normal human tissues was studied by
Northern analysis. Greatest MDC gene expression was ob-
served in the thymus, with much weaker expression in spleen
and lung (Fig. 6). Very faint expression of MDC was seen
in the small intestine, and no expression was detected in brain,
colon, heart, kidney, liver, ovary, pancreas, placenta, pros-
tate, skeletal muscle, testis, or peripheral blood leukocytes.
Biological Activity of MDC. The mature form of MDC
was chemically synthesized for use in biological assays. Syn-
thetic chemokines have been shown to fold correctly and
retain the biological activity of the natural species (47–49).
To confirm that synthetic MDC was in fact correctly
folded, formation of the disulfide bridges was confirmed by
Figure 4. Northern analysis of MDC mRNA expression in human
cells. Migration of MDC, 28S RNA, and 18S RNA is indicated. (A) Pe-
ripheral blood monocytes were allowed to differentiate into macrophages
by incubation on plastic tissue culture dishes for 6 d (41). Total RNA was
isolated from individual dishes on the indicated days, fractionated through
a formaldehyde agarose gel, blotted, and probed with the radiolabeled
MDC cDNA. The blot was subsequently probed for GAPDH message.
(B) Expression of MDC in differentiated HL-60 cells. Cells were treated
with PMA to induce differentiation to monocytic cells or with DMSO to
induce granulocytic cells. MDC expression was analyzed by Northern
blotting as in A. (C) Northern blot of MDC expression in human periph-
eral blood monocytes (Mono.), macrophages derived from these mono-
cytes (Mac.), dendritic cells derived from PBMC of two different donors
(DC-1 and DC-2), and natural killer cells derived from PBMC (NK). (D)
Expression of MDC in cell cultures. Lung epithelial cell line A549, lung
fibroblast line IMR90, and I-HUVEC without and with TNF-a stimula-
tion; PBMC without and with stimulation by PHA and PMA; and
monocyte derived macrophages after 6 d in culture. After probing with
MDC, the filter was stripped and probed sequentially with MCP-1 and
GAPDH.1600 Macrophage-derived Chemokine, a Novel Chemoattractant
peptide mapping. The behavior of chemically synthesized
MDC was identical to that of CHO-derived MDC in the
following procedures: SDS-PAGE, heparin–Sepharose chro-
matography, and immunoprecipitation and Western blot-
ting with mAbs or polyclonal antibodies raised against re-
combinant MDC (data not shown).
A microchamber migration assay was used to study the
chemotactic activity of MDC upon dendritic cells and IL-2–
activated natural killer cells, both derived from human
PBMC. Both of these cell types migrated toward MDC
with a bell-shaped dose-response curve. Migration became
significant at 0.1 ng/ml (P ,0.05) and reached a maximum
at 1 ng/ml MDC (P ,0.01) (Fig. 7). At the optimal con-
centration of 1 ng/ml, the number of dendritic cells that
migrated to MDC was 87 6 18% (n 5 7) of that respond-
ing to 100 ng/ml MCP-3, a reference chemoattractant for
dendritic cells (42).
A similar assay was used to measure the chemotactic re-
sponse of PBMC to MDC. Significant migration occurred
at 1 ng/ml MDC (P ,0.05), and the response peaked at
Figure 5. MDC protein expression in human monocyte–derived mac-
rophages and unstimulated epithelial cell lines. Monocytes were differenti-
ated into macrophages by incubation on tissue culture plastic for 6 d. LDL
or oxidized LDL was then added for an additional 3 d. Culture supernatants
from these macrophages or from epithelial lines were passed over heparin–
Sepharose columns, and MDC was eluted with 0.6 M NaCl, fractionated
by SDS-PAGE, and reacted with an mAb raised against recombinant MDC
produced in bacteria. (Top) The Coomassie stained gel of the heparin–
Sepharose elutates. (Bottom) The Western blot. Lanes 1, CHO-derived
MDC; 2, A549 epithelial cell; 3, T84 epithelial cell; 4, macrophage, day 6;
5, macrophage, day 9; 6, macrophage plus LDL, day 9; 7, macrophage
plus oxidized LDL, day 9. Arrows indicate the migration of MDC.
Figure 6. Expression of MDC mRNA in normal human tissues. A
multiple tissue Northern blot was probed with the MDC cDNA se-
quence and washed at high stringency (0.23 SSC, 508C). The migration
of RNA size markers is indicated in kb.
Figure 7. Chemotaxis of
monocyte-derived dendritic cells
and IL-2–activated natural killer
cells induced by MDC. (Top)
PBMC were isolated by density
gradient centrifugation and de-
pleted of CD191 and CD21 cells
by antibody-coated magnetic
beads. Dendritic cells were ob-
tained by culturing the remain-
ing cells for 6 to 8 d in RPMI
containing containing 10% FCS,
50 ng/ml GM-CSF, and 20 ng/
ml IL-13. (Bottom) Natural killer
cells were purified by discontin-
uous Percoll gradient centrifuga-
tion of monocyte-depleted
PBMC, followed by negative se-
lection of T cells by panning
with an anti-CD6 mAb. Cells
were cultured with an irradiated
lymphoblastoid cell line in the
presence of 250 U/ml IL-2. For
chemotaxis assays, cells were
added to the upper wells of a microchamber and medium (RPMI plus 1%
FCS) with or without chemokine was added to the lower chamber.
The figure shows representative experiments. Values represent the num-
ber of migrated cells (mean 6 SE) after subtraction of basal migration
(24 6 3 for dendritic cells and 20 6 6 for natural killer cells). *P ,0.05),
**P ,0.01.
Figure 8. Chemotaxis of
monocytes induced by MDC.
Human PBMC were purified by
density gradient centrifugation
and resuspended in RPMI plus
1% FCS. Chemotaxis was as-
sayed as described in Fig. 7; two
independent experiments are il-
lustrated. Under these condi-
tions, only monocytes migrated
through the filter. Basal migra-
tion of 15 6 2 (top) and 16 6 2
(bottom) was subtracted from the
values shown. The response of
these cells to 100 ng/ml MCP-3
was 42 6 4 and to 10 nM fMLP
was 54 6 3.1601 Godiska et al.
100 ng/ml (Fig. 8). Under these conditions, only mono-
cytes had migrated through the filter. The peak number of
cells was equivalent to that migrating to 100 ng/ml MCP-3
(data not shown).
Under similar assay conditions, MDC was not chemo-
tactic for neutrophils at concentrations up to 1 mg/ml (data
not shown).
Chromosome Localization. PCR was used to screen for
the MDC gene in genomic DNA isolated from a set of
mouse–human or hamster–human chimeric cell lines, each
of which retains a single human chromosome. The ex-
pected PCR product was produced only from the line
containing human chromosome 16. The identity of the
PCR band was confirmed by hybridization with an internal
MDC oligonucleotide (data not shown).
Discussion
We have described the cloning and activity of a novel
human CC chemokine, MDC. This sequence was not pre-
viously represented in the Expressed Sequence Tags (dbest)
or Non-Redundant (nr) databases of GenBank. The amino
acid sequence of MDC suggests that it is a member of the
CC chemokine family, but it is not closely related to any of
the known chemokines. The length of the 39 noncoding
region is unusually long and contains multiple Alu repeats.
The size of the MDC transcript corresponds well to the
size of the cDNA (Figs. 4 and 5), confirming that the entire
cDNA is transcribed.
Our results indicate that MDC has a very specific pattern
of expression. It was highly expressed by fully differentiated
macrophages and monocyte-derived dendritic cells, but it
was not expressed by freshly isolated monocytes, granulo-
cytic cells, or natural killer cells (Fig. 4). The timing of
MDC expression in macrophages cultured in vitro appears
to be similar to that of the transferrin receptor, which is
also strongly upregulated late in macrophage differentiation
(6 d after plating; 50). The kinetics of induction of other
macrophage-specific products is quite different. For exam-
ple, platelet activating factor acetylhydrolase is highly up-
regulated by day 2 (36), and chitinase is strongly induced
beginning at day 9 (51).
The activity and expression pattern of MDC have several
implications in the function of dendritic cells. Immature
dendritic cells are rapidly recruited to sites of inflammatory
stimulation and are highly proficient in antigen uptake. Af-
ter antigenic stimulation, they are again mobilized and mi-
grate to draining lymph nodes. During this process of mat-
uration, they lose their ability to process and present
soluble antigen and become extemely potent stimulators of
T lymphocytes (52–55). Consequently, dendritic cells have
been implicated in organ transplant rejection, HIV infec-
tion, asthma, and induction of tolerance (56). Because MDC
is highly expressed by dendritic cells and is also chemotactic
for them, it may play an autocrine role in their accumu-
lation at sites of inflammation. In addition, several other
chemokines, including MCP-3, MIP-1a, and RANTES,
are chemotactic for immature dendritic cells (42), but do
not induce their maturation (Sozzani, S., and P. Allavena,
unpublished data). Thus, chemokines may play a major role
in the initial influx of immature dendritic cells. Administra-
tion of TNF-a also leads to accumulation of dendritic cells
in vivo (57); however, this effect may be indirectly medi-
ated by factors induced by TNF-a, including CC chemo-
kines. Unlike the chemokines, TNF-a induces maturation
of dendritic cells, decreasing their antigen uptake and in-
creasing their ability to stimulate T cells (43).
The high expression of MDC in the thymus suggests it
has an additional (or alternate) function in T cell develop-
ment. One possible role is to attract or retain dendritic cells in
the thymus to enhance stimulation of T cells. In addition,
MDC may be chemotactic for T cells themselves and thereby
aid in their aggregation with dendritic cells. Notably, the
CC chemokine TARC, which is specifically chemotactic
for T cells, has a tissue-specific expression pattern that is
nearly identical to that of MDC, with very high expression
in the thymus (20). TARC, which is z32% identical to
MDC, is also the only other chemokine known to be
encoded on chromosome 16 (58). The effect of MDC on
T cells is currently being investigated.
Natural killer cells recognize a broad range of cytolytic
targets and are believed to be involved in defense against
viral infection, destruction of tumor cells, and regulation of
hematopoiesis. The means by which they select a specific
target cell is poorly understood, but their activity appears to
involve an extensive set of cytokines that includes interleu-
kins, interferons, and chemokines (59, 60). Granule exocy-
tosis or chemotaxis of natural killer cells has been demon-
strated in response to many CC chemokines, such as MCP-1,
-2, and -3 (49, 61, 62), MIP-1a (63), MIP-1b (49), and
RANTES (61). Further, these cells respond to the CXC
chemokines IP-10 (63) and IL-8 (64), and migrate toward
the C chemokine, lymphotactin (65). Our results indicate that
MDC likewise induces directed migration of IL-2–activated
natural killer cells, with an effective concentration in the low
nanomolar range.
Monocytes also exhibited a dose-dependent chemotactic
response to MDC. The magnitude of the response was
similar to that of monocyte-derived dendritic cells and acti-
vated natural killer cells, but it occurred at a 100-fold
higher concentration of MDC (Fig. 8). Thus, in vivo pro-
duction of MDC may first attract dendritic cells or natural
killer cells, and further accumulation of MDC may cause a
subsequent influx of monocytes.
Induction of MDC expression does not follow the pat-
tern typically observed for chemokines. These genes are gen-
erally not constitutively expressed, but they can be strongly
induced by cytokine treatment (e.g., TNF-a induction of
MCP-1; Fig. 4). In marked contrast, induction of MDC
was not detected after proinflammatory stimulation of
PBMC with PHA plus PMA or stimulation of lung epithe-
lial cells (A549), lung fibroblast cells (IMR90), or I-HUVEC
with TNF-a (Figs. 4 and 5). Similarly, treatment with LDL
seemed to have little effect on production of MDC protein
by macrophages, although a transient rise in MDC mRNA
expression may not have been detected in this study. LDL1602 Macrophage-derived Chemokine, a Novel Chemoattractant
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